Revolution Medicines, Inc. Marketable Securities (Current)
Revolution Medicines, Inc. (RVMD) had Marketable Securities (Current) of $3.12 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-05
- 2026-06-30: Marketable Securities, Current $3.12B.
- 2026-03-31: Marketable Securities, Current $1.47B.
- 2025-12-31: Marketable Securities, Current $1.64B.
- 2025-09-30: Marketable Securities, Current $1.71B.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $3.12B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.47B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.64B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.71B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.73B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.77B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $1.75B 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.35B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.32B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.42B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.16B 10-K · filed 2025-02-26 |
| 2023-09-30 | $454.80M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $529.16M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $482.58M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $483.53M 10-K · filed 2024-02-26 |
| 2022-09-30 | $476.07M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $355.65M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $421.09M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $468.56M 10-K · filed 2023-02-27 |
| 2021-09-30 | $479.50M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $450.72M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $330.00M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $336.47M 10-K · filed 2022-02-28 |
| 2020-09-30 | $401.27M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $301.47M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $165.28M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $106.10M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |